Many men begin testosterone replacement therapy expecting their sexual function to improve across the board—better libido, stronger erections, enhanced satisfaction. And while TRT often delivers significant benefits for desire and overall sexual activity, the evidence tells a more nuanced story when it comes to erectile function specifically. Understanding this distinction is crucial for setting realistic expectations and developing comprehensive treatment strategies.
The latest clinical data, including findings from the landmark TRAVERSE trial published in 2024, confirms what experienced clinicians have long observed: testosterone powerfully influences libido and sexual desire, but erectile function often requires additional interventions—particularly in men with moderate to severe ED or significant vascular disease. This doesn't mean TRT fails; it means that optimizing sexual function requires understanding the distinct mechanisms underlying desire versus erection.
This comprehensive guide examines the evidence on testosterone's effects on sexual function, explains when TRT alone may be sufficient versus when combination therapy is needed, and reviews the full spectrum of treatment options available when testosterone optimization doesn't fully resolve erectile difficulties.
1. Erectile Function (EF): Ability to achieve and maintain erections sufficient for penetration
2. Orgasmic Function: Ability to reach orgasm during sexual activity
3. Sexual Desire (SD): Frequency and intensity of interest in sexual activity—this is "libido"
4. Intercourse Satisfaction: Satisfaction with sexual intercourse
5. Overall Satisfaction: Overall satisfaction with sex life
Testosterone has its strongest, most consistent effect on sexual desire—the motivation and interest in sexual activity. This makes biological sense: testosterone influences the brain's reward circuitry, attentiveness to erotic cues, sexual thoughts and fantasies, and spontaneous arousal. Men with hypogonadism commonly report that their interest in sex returns within weeks of starting TRT, often before any changes in erectile quality are noticed.
Erectile function, by contrast, depends heavily on vascular and neural mechanisms that testosterone influences but does not directly control. Erections require intact endothelial function, adequate nitric oxide production, functional smooth muscle relaxation in the corpus cavernosum, and proper venous occlusion. When these mechanisms are impaired by diabetes, atherosclerosis, hypertension, neurological damage, or aging, simply restoring testosterone levels may not be sufficient to overcome the underlying pathology.
Key Findings:
• Sexual Activity Improved: Men on TRT showed significantly greater improvements in overall sexual activity compared to placebo, with benefits sustained throughout the two-year treatment period.
• Hypogonadal Symptoms Improved: Scores on the Hypogonadal Symptom Questionnaire improved significantly with TRT, indicating broad symptomatic relief.
• Sexual Desire Improved: Libido scores showed meaningful improvement with testosterone treatment.
• Erectile Function Did NOT Significantly Improve: Perhaps most notably, changes in IIEF-5 (erectile function) scores did not differ significantly between TRT and placebo groups at either 12 or 24 months. The estimated between-group difference was just 0.6 points at 12 months and -0.2 points at 24 months—well below the 4-point threshold considered clinically meaningful.
Interpretation: In men with hypogonadism, cardiovascular disease or risk factors, and documented low libido, TRT for two years improved desire and overall sexual activity but did not significantly improve the ability to achieve and maintain erections. This finding aligns with the understanding that erectile dysfunction in this population often has significant vascular etiology that testosterone alone cannot overcome.
However, the magnitude of erectile function improvement was modest. The effect was most pronounced in men with the lowest baseline testosterone levels (<8 nmol/L or <230 ng/dL) and in those with mild rather than moderate or severe ED. Men with total testosterone >10 nmol/L (>290 ng/dL) at baseline showed less benefit, suggesting a threshold effect.
• Baseline testosterone is severely low (<250 ng/dL)
• ED severity is mild (IIEF-EF score 17-25)
• The primary complaint is low desire with secondary erectile difficulties
• Vascular risk factors (diabetes, hypertension, dyslipidemia) are minimal or well-controlled
• No history of pelvic surgery, radiation, or neurological conditions affecting erection
Conversely, men with moderate-to-severe ED (IIEF-EF <17), significant cardiovascular disease, diabetes with neuropathy, or post-prostatectomy ED should expect that TRT will likely improve desire but may require additional therapies to adequately address erectile function.
• NOS Expression: Testosterone upregulates nitric oxide synthase (NOS) in penile tissue, increasing the substrate on which PDE5 inhibitors act
• PDE5 Regulation: Testosterone modulates PDE5 expression; low testosterone may alter the enzyme profile in ways that reduce drug efficacy
• Central Effects: Testosterone enhances libido and central arousal, providing the "demand signal" that triggers nitric oxide release in the first place
• Structural Integrity: Testosterone maintains the smooth muscle and vascular health of the corpus cavernosum
Sildenafil Non-Responder Rescue: A multicenter study found that adding testosterone gel 1% to sildenafil in hypogonadal men who had previously failed sildenafil alone resulted in significant improvements in erectile function, orgasmic function, and patient satisfaction. This "rescue" approach converted previous non-responders to responders.
2020 Meta-Analysis: A meta-analysis of eight studies (913 patients) confirmed that testosterone plus PDE5 inhibitor combination therapy produced significantly greater improvements in IIEF-EF scores than PDE5 inhibitors plus placebo (pooled SMD 0.663, P<0.0001). The effect was most pronounced in men with lower baseline testosterone and lower baseline erectile function scores.
PDE5 Inhibitor Options for Combination with TRT
Clinical Pearl: Daily low-dose tadalafil (5mg) is increasingly popular among men on TRT because it provides continuous erectile support without timing constraints, may improve endothelial function over time, and also helps with lower urinary tract symptoms common in older men. This "lifestyle dosing" approach pairs particularly well with testosterone therapy.
• Alprostadil (Prostaglandin E1): The most commonly used single agent; relaxes smooth muscle via cAMP pathway independent of nitric oxide
• Trimix: Combination of alprostadil, papaverine, and phentolamine; allows lower doses of each agent, reducing side effects while maximizing efficacy. Response rates >90%
• Quadmix: Adds atropine to the Trimix formulation; may provide additional benefit in certain patients
Injection therapy requires training on proper technique, dosage titration, and recognition of complications (priapism, fibrosis). When properly managed, it provides reliable erections for men who have failed all oral options.
Mechanism: PT-141 activates melanocortin-4 receptors (MC4R) in the hypothalamus, triggering the neurological cascade associated with sexual arousal. It also promotes nitric oxide release, potentially supporting erectile function as a secondary effect.
FDA Status: Currently approved only for hypoactive sexual desire disorder (HSDD) in premenopausal women, but used off-label in men with low libido and/or ED who don't respond to conventional therapies.
Clinical Evidence in Men: A 2024 observational study reported that 80% of men using PT-141 experienced improved sexual satisfaction, 39% noted improvement in desire, and 52% reported better erectile function. Combination with PDE5 inhibitors produced enhanced responses in previous non-responders.
Dosing: 1.75mg subcutaneous injection administered 45 minutes before sexual activity. Maximum one dose per 24 hours, no more than 8 doses per month.
Best Candidates: Men whose primary issue is low desire (even on TRT), those with psychological or neurological contributions to ED, and PDE5 inhibitor non-responders who want to try combination therapy.
For men who fail all medical therapies, penile prosthesis implantation offers a definitive surgical solution. Inflatable three-piece prostheses provide on-demand rigidity and high patient satisfaction rates (>90%). This is typically considered after exhausting other options but can be transformative for men with severe, refractory ED.
Important information: When Testosterone Doesn’t Lead to Better Erections or Sex Drive - Excel Male Health Forum
Importantly, erectile function improvements plateau at a lower testosterone threshold than libido improvements. A man with testosterone of 350 ng/dL may have near-normal erectile function but significantly reduced desire. This helps explain why TRT more reliably improves libido than erectile function—the threshold for libido optimization is higher.
The goal is not to suppress estradiol but to maintain a balanced testosterone-to-estradiol ratio. Most men do well with estradiol levels in the 20-40 pg/mL range. Routine aromatase inhibitor use is not recommended and may actually worsen sexual function by driving estradiol too low.
• Cardiovascular health: exercise, blood pressure control, statin therapy when indicated
• Metabolic health: glucose control, weight management, insulin sensitivity
• Mental health: depression, anxiety, stress management, relationship factors
• Sleep quality: sleep apnea screening and treatment
• Medications: review for drugs that cause ED (beta-blockers, SSRIs, finasteride)
• Pelvic floor health: particularly important for men with prostatectomy or radiation history
Ensure adequate TRT dosing with trough testosterone >500 ng/dL. Allow 3-6 months for full effect on libido. Address estradiol only if symptomatic and levels are clearly out of range.
Step 2: Add PDE5 Inhibitor if Erectile Function Insufficient
Most men benefit from starting with on-demand sildenafil or tadalafil, titrating to maximum dose if needed. Consider daily tadalafil 5mg for convenience and potential endothelial benefits.
Step 3: Optimize PDE5 Inhibitor Use
If initial PDE5 inhibitor trial fails, ensure proper usage (timing, food restrictions, adequate sexual stimulation). Try alternative PDE5 inhibitors. Consider daily dosing for 4-6 weeks before declaring failure.
Step 4: Consider Adding PT-141 or Advancing to Injections
For persistent low desire despite optimized testosterone, PT-141 may provide the central arousal component. For refractory ED, intracavernosal injection therapy (Trimix) offers high efficacy.
Step 5: Surgical Options
When all medical therapies fail, penile prosthesis implantation provides a definitive solution with high satisfaction rates.
The good news is that effective treatments exist at every level. PDE5 inhibitors combined with optimized testosterone address the needs of most men. For those who don't respond, PT-141, intracavernosal injections, and surgical options provide additional pathways to satisfactory sexual function.
The key is understanding that sexual health involves multiple interacting systems—hormonal, vascular, neural, and psychological—and that comprehensive treatment often requires addressing multiple components. With appropriate evaluation, realistic goal-setting, and a stepwise approach to therapy, most men can achieve meaningful improvements in their sexual function and satisfaction.
• PT-141 Works Great, Maybe Too Good – Real-world experiences with bremelanotide for libido enhancement
• TRT and ED: When Testosterone Isn't Enough – Forum discussion on combination therapy approaches
• Daily Cialis vs On-Demand: What Works Better – Comparing PDE5 inhibitor dosing strategies
• Trimix Success Stories and Protocols – Intracavernosal injection experiences and dosing
• Optimizing Estradiol for Sexual Function – The role of estrogen balance in male sexuality
2. Xu Z, et al. Updated systematic review and meta-analysis of TRT on erectile function and prostate. Front Endocrinol. 2024. [PMC Full Text]
3. Lee H, et al. Testosterone replacement in men with sexual dysfunction. Cochrane Database Syst Rev. 2024. [Cochrane Library]
4. Zhu J, et al. Do testosterone supplements enhance response to PDE5 inhibitors in men with ED and hypogonadism: A meta-analysis. Transl Androl Urol. 2020. [PMC Full Text]
5. Buvat J, et al. TADTEST Study: Hypogonadal men nonresponders to tadalafil benefit from testosterone normalization. J Sex Med. 2011. [PubMed]
6. Corona G, et al. Testosterone Therapy Improves Erectile Function and Libido in Hypogonadal Men. Curr Opin Urol. 2017. [PMC Full Text]
7. Aversa A, et al. Synergetic effect of testosterone and PDE-5 inhibitors in hypogonadal men with ED. Int J Androl. 2012. [PMC Full Text]
8. Bremelanotide (PT-141): Mechanism and clinical evidence. J Sex Med. [PMC Full Text]
9. La Vignera S, et al. Androgen Deficiency and PDE5 Expression Changes in Aging Male. Front Endocrinol. 2019. [Frontiers Full Text]
10. Relationship Between Testosterone and Erectile Dysfunction. World J Urol. [PMC Full Text]
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Sexual dysfunction can have multiple causes requiring individualized evaluation. All medications discussed require prescriptions and should be used under medical supervision. PT-141 use in men is off-label. Consult a qualified healthcare provider for personalized recommendations.
About ExcelMale.com: ExcelMale is a men's health forum with over 24,000 members and 20+ years of archived discussions on testosterone replacement therapy, hormone optimization, and sexual health. Founded by Nelson Vergel, author of Testosterone: A Man's Guide and Beyond Testosterone, ExcelMale provides evidence-based information and peer support for men navigating hormone health decisions.
The latest clinical data, including findings from the landmark TRAVERSE trial published in 2024, confirms what experienced clinicians have long observed: testosterone powerfully influences libido and sexual desire, but erectile function often requires additional interventions—particularly in men with moderate to severe ED or significant vascular disease. This doesn't mean TRT fails; it means that optimizing sexual function requires understanding the distinct mechanisms underlying desire versus erection.
This comprehensive guide examines the evidence on testosterone's effects on sexual function, explains when TRT alone may be sufficient versus when combination therapy is needed, and reviews the full spectrum of treatment options available when testosterone optimization doesn't fully resolve erectile difficulties.
Libido vs. Erectile Function: Understanding the Critical Distinction
Sexual function encompasses multiple distinct domains, and conflating them leads to confusion about what treatments can realistically achieve. The International Index of Erectile Function (IIEF), the gold-standard assessment tool, measures five separate domains:1. Erectile Function (EF): Ability to achieve and maintain erections sufficient for penetration
2. Orgasmic Function: Ability to reach orgasm during sexual activity
3. Sexual Desire (SD): Frequency and intensity of interest in sexual activity—this is "libido"
4. Intercourse Satisfaction: Satisfaction with sexual intercourse
5. Overall Satisfaction: Overall satisfaction with sex life
Testosterone has its strongest, most consistent effect on sexual desire—the motivation and interest in sexual activity. This makes biological sense: testosterone influences the brain's reward circuitry, attentiveness to erotic cues, sexual thoughts and fantasies, and spontaneous arousal. Men with hypogonadism commonly report that their interest in sex returns within weeks of starting TRT, often before any changes in erectile quality are noticed.
Erectile function, by contrast, depends heavily on vascular and neural mechanisms that testosterone influences but does not directly control. Erections require intact endothelial function, adequate nitric oxide production, functional smooth muscle relaxation in the corpus cavernosum, and proper venous occlusion. When these mechanisms are impaired by diabetes, atherosclerosis, hypertension, neurological damage, or aging, simply restoring testosterone levels may not be sufficient to overcome the underlying pathology.
What the Research Shows: TRT's Effects on Sexual Function
The TRAVERSE Trial Sexual Function Substudy (2024)
The TRAVERSE trial was the largest cardiovascular safety study of TRT ever conducted, enrolling over 5,200 middle-aged and older men with hypogonadism. Nested within the main trial was a Sexual Function Study of 1,161 men with documented low libido, randomized to testosterone gel or placebo for up to two years.Key Findings:
• Sexual Activity Improved: Men on TRT showed significantly greater improvements in overall sexual activity compared to placebo, with benefits sustained throughout the two-year treatment period.
• Hypogonadal Symptoms Improved: Scores on the Hypogonadal Symptom Questionnaire improved significantly with TRT, indicating broad symptomatic relief.
• Sexual Desire Improved: Libido scores showed meaningful improvement with testosterone treatment.
• Erectile Function Did NOT Significantly Improve: Perhaps most notably, changes in IIEF-5 (erectile function) scores did not differ significantly between TRT and placebo groups at either 12 or 24 months. The estimated between-group difference was just 0.6 points at 12 months and -0.2 points at 24 months—well below the 4-point threshold considered clinically meaningful.
Interpretation: In men with hypogonadism, cardiovascular disease or risk factors, and documented low libido, TRT for two years improved desire and overall sexual activity but did not significantly improve the ability to achieve and maintain erections. This finding aligns with the understanding that erectile dysfunction in this population often has significant vascular etiology that testosterone alone cannot overcome.
2024 Meta-Analysis: TRT and Erectile Function
A comprehensive 2024 meta-analysis published in Frontiers in Endocrinology pooled data from randomized controlled trials of TRT in men with late-onset hypogonadism. The analysis found that TRT significantly improved IIEF scores compared to placebo, regardless of administration method (injections, gels, or oral) or treatment duration. Importantly, this improvement occurred without worsening lower urinary tract symptoms, prostate volume, or PSA levels.However, the magnitude of erectile function improvement was modest. The effect was most pronounced in men with the lowest baseline testosterone levels (<8 nmol/L or <230 ng/dL) and in those with mild rather than moderate or severe ED. Men with total testosterone >10 nmol/L (>290 ng/dL) at baseline showed less benefit, suggesting a threshold effect.
When TRT Works Best for Erectile Function
Based on the totality of evidence, TRT as monotherapy is most likely to meaningfully improve erectile function when:• Baseline testosterone is severely low (<250 ng/dL)
• ED severity is mild (IIEF-EF score 17-25)
• The primary complaint is low desire with secondary erectile difficulties
• Vascular risk factors (diabetes, hypertension, dyslipidemia) are minimal or well-controlled
• No history of pelvic surgery, radiation, or neurological conditions affecting erection
Conversely, men with moderate-to-severe ED (IIEF-EF <17), significant cardiovascular disease, diabetes with neuropathy, or post-prostatectomy ED should expect that TRT will likely improve desire but may require additional therapies to adequately address erectile function.
When TRT Isn't Enough: The Role of PDE5 Inhibitors
Phosphodiesterase type 5 (PDE5) inhibitors—sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra)—remain the first-line medical therapy for erectile dysfunction. These drugs work by enhancing the effect of nitric oxide in penile tissue, promoting smooth muscle relaxation and blood flow. Importantly, testosterone influences the expression and activity of PDE5 enzymes, creating a biological rationale for combining TRT with PDE5 inhibitors.The Synergy Between Testosterone and PDE5 Inhibitors
Multiple studies have demonstrated that hypogonadal men have reduced responsiveness to PDE5 inhibitors—and that restoring testosterone can convert non-responders to responders. The mechanism involves several pathways:• NOS Expression: Testosterone upregulates nitric oxide synthase (NOS) in penile tissue, increasing the substrate on which PDE5 inhibitors act
• PDE5 Regulation: Testosterone modulates PDE5 expression; low testosterone may alter the enzyme profile in ways that reduce drug efficacy
• Central Effects: Testosterone enhances libido and central arousal, providing the "demand signal" that triggers nitric oxide release in the first place
• Structural Integrity: Testosterone maintains the smooth muscle and vascular health of the corpus cavernosum
Key Combination Therapy Studies
The TADTEST Study: In this randomized trial, hypogonadal men who failed to respond to tadalafil (Cialis) alone were given testosterone gel or placebo in addition to continued tadalafil. Those receiving the combination showed significant improvements in IIEF-EF scores compared to placebo plus tadalafil. Notably, the benefit was greatest in men with baseline testosterone ≤3 ng/mL (300 ng/dL).Sildenafil Non-Responder Rescue: A multicenter study found that adding testosterone gel 1% to sildenafil in hypogonadal men who had previously failed sildenafil alone resulted in significant improvements in erectile function, orgasmic function, and patient satisfaction. This "rescue" approach converted previous non-responders to responders.
2020 Meta-Analysis: A meta-analysis of eight studies (913 patients) confirmed that testosterone plus PDE5 inhibitor combination therapy produced significantly greater improvements in IIEF-EF scores than PDE5 inhibitors plus placebo (pooled SMD 0.663, P<0.0001). The effect was most pronounced in men with lower baseline testosterone and lower baseline erectile function scores.
PDE5 Inhibitor Options for Combination with TRT
Drug | Onset | Duration | Dosing Options | Best For |
| Sildenafil (Viagra) | 30-60 min | 4-5 hours | 25, 50, 100mg on-demand | Planned activity; cost-conscious patients |
Tadalafil (Cialis) | 30-60 min | 24-36 hours | 5mg daily OR 10-20mg on-demand | Spontaneity; BPH symptoms; daily use |
Vardenafil (Levitra) | 25-60 min | 4-5 hours | 5, 10, 20mg on-demand | Sildenafil alternative; may work faster for some |
Avanafil (Stendra) | 15-30 min | 6+ hours | 50, 100, 200mg on-demand | Fastest onset; fewer side effects |
Beyond PDE5 Inhibitors: Advanced ED Treatments
Up to 30-40% of men do not respond adequately to PDE5 inhibitors, even with testosterone optimization. For these patients, several second-line and emerging therapies exist.Intracavernosal Injection Therapy
Direct injection of vasoactive medications into the corpus cavernosum bypasses many of the vascular and neural pathways that PDE5 inhibitors depend on. This approach has response rates exceeding 85-90% in patients who fail oral therapy.• Alprostadil (Prostaglandin E1): The most commonly used single agent; relaxes smooth muscle via cAMP pathway independent of nitric oxide
• Trimix: Combination of alprostadil, papaverine, and phentolamine; allows lower doses of each agent, reducing side effects while maximizing efficacy. Response rates >90%
• Quadmix: Adds atropine to the Trimix formulation; may provide additional benefit in certain patients
Injection therapy requires training on proper technique, dosage titration, and recognition of complications (priapism, fibrosis). When properly managed, it provides reliable erections for men who have failed all oral options.
PT-141 (Bremelanotide): Addressing Desire at the Source
PT-141 (bremelanotide/Vyleesi) represents a fundamentally different approach to sexual dysfunction. Unlike PDE5 inhibitors that work on blood flow, PT-141 is a melanocortin receptor agonist that acts directly on the brain's arousal centers to stimulate sexual desire.Mechanism: PT-141 activates melanocortin-4 receptors (MC4R) in the hypothalamus, triggering the neurological cascade associated with sexual arousal. It also promotes nitric oxide release, potentially supporting erectile function as a secondary effect.
FDA Status: Currently approved only for hypoactive sexual desire disorder (HSDD) in premenopausal women, but used off-label in men with low libido and/or ED who don't respond to conventional therapies.
Clinical Evidence in Men: A 2024 observational study reported that 80% of men using PT-141 experienced improved sexual satisfaction, 39% noted improvement in desire, and 52% reported better erectile function. Combination with PDE5 inhibitors produced enhanced responses in previous non-responders.
Dosing: 1.75mg subcutaneous injection administered 45 minutes before sexual activity. Maximum one dose per 24 hours, no more than 8 doses per month.
Best Candidates: Men whose primary issue is low desire (even on TRT), those with psychological or neurological contributions to ED, and PDE5 inhibitor non-responders who want to try combination therapy.
Vacuum Erection Devices and Penile Prostheses
Vacuum erection devices (VEDs) remain a non-pharmacological option that can work regardless of vascular or neural status. Modern devices are discreet and effective, though some men find them cumbersome or report less natural-feeling erections.For men who fail all medical therapies, penile prosthesis implantation offers a definitive surgical solution. Inflatable three-piece prostheses provide on-demand rigidity and high patient satisfaction rates (>90%). This is typically considered after exhausting other options but can be transformative for men with severe, refractory ED.
Important information: When Testosterone Doesn’t Lead to Better Erections or Sex Drive - Excel Male Health Forum
Optimizing TRT for Sexual Function: Practical Considerations
Target Testosterone Levels
Evidence suggests that sexual function benefits from testosterone levels in the mid-to-high normal range. While there's no universal "optimal" level, clinical experience and research data support targeting trough testosterone levels of 500-700 ng/dL for most men seeking sexual function optimization. Some men may require levels >600 ng/dL to fully restore libido, while others do well at lower levels.Importantly, erectile function improvements plateau at a lower testosterone threshold than libido improvements. A man with testosterone of 350 ng/dL may have near-normal erectile function but significantly reduced desire. This helps explain why TRT more reliably improves libido than erectile function—the threshold for libido optimization is higher.
Managing Estradiol
Estradiol (E2) plays an important but often underappreciated role in male sexual function. While excessive estradiol can cause symptoms like water retention and gynecomastia, estrogen is actually necessary for libido, erectile function, and overall sexual satisfaction in men. Studies show that both very low and very high estradiol levels are associated with sexual dysfunction.The goal is not to suppress estradiol but to maintain a balanced testosterone-to-estradiol ratio. Most men do well with estradiol levels in the 20-40 pg/mL range. Routine aromatase inhibitor use is not recommended and may actually worsen sexual function by driving estradiol too low.
Addressing Contributing Factors
Sexual function is influenced by many factors beyond testosterone levels. Optimizing TRT outcomes requires attention to:• Cardiovascular health: exercise, blood pressure control, statin therapy when indicated
• Metabolic health: glucose control, weight management, insulin sensitivity
• Mental health: depression, anxiety, stress management, relationship factors
• Sleep quality: sleep apnea screening and treatment
• Medications: review for drugs that cause ED (beta-blockers, SSRIs, finasteride)
• Pelvic floor health: particularly important for men with prostatectomy or radiation history
A Practical Treatment Algorithm
Step 1: Optimize TestosteroneEnsure adequate TRT dosing with trough testosterone >500 ng/dL. Allow 3-6 months for full effect on libido. Address estradiol only if symptomatic and levels are clearly out of range.
Step 2: Add PDE5 Inhibitor if Erectile Function Insufficient
Most men benefit from starting with on-demand sildenafil or tadalafil, titrating to maximum dose if needed. Consider daily tadalafil 5mg for convenience and potential endothelial benefits.
Step 3: Optimize PDE5 Inhibitor Use
If initial PDE5 inhibitor trial fails, ensure proper usage (timing, food restrictions, adequate sexual stimulation). Try alternative PDE5 inhibitors. Consider daily dosing for 4-6 weeks before declaring failure.
Step 4: Consider Adding PT-141 or Advancing to Injections
For persistent low desire despite optimized testosterone, PT-141 may provide the central arousal component. For refractory ED, intracavernosal injection therapy (Trimix) offers high efficacy.
Step 5: Surgical Options
When all medical therapies fail, penile prosthesis implantation provides a definitive solution with high satisfaction rates.
Conclusion: Setting Realistic Expectations
Testosterone replacement therapy is a powerful tool for restoring sexual desire, overall sexual activity, and quality of life in hypogonadal men. However, the expectation that TRT alone will fully resolve erectile dysfunction is often unrealistic, particularly for men with significant vascular disease, diabetes, neurological conditions, or moderate-to-severe baseline ED.The good news is that effective treatments exist at every level. PDE5 inhibitors combined with optimized testosterone address the needs of most men. For those who don't respond, PT-141, intracavernosal injections, and surgical options provide additional pathways to satisfactory sexual function.
The key is understanding that sexual health involves multiple interacting systems—hormonal, vascular, neural, and psychological—and that comprehensive treatment often requires addressing multiple components. With appropriate evaluation, realistic goal-setting, and a stepwise approach to therapy, most men can achieve meaningful improvements in their sexual function and satisfaction.
Related ExcelMale Forum Discussions
Explore these community discussions for additional insights:• PT-141 Works Great, Maybe Too Good – Real-world experiences with bremelanotide for libido enhancement
• TRT and ED: When Testosterone Isn't Enough – Forum discussion on combination therapy approaches
• Daily Cialis vs On-Demand: What Works Better – Comparing PDE5 inhibitor dosing strategies
• Trimix Success Stories and Protocols – Intracavernosal injection experiences and dosing
• Optimizing Estradiol for Sexual Function – The role of estrogen balance in male sexuality
Key References
1. Pencina KM, Travison TG, Cunningham GR, et al. Effect of TRT on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism. J Clin Endocrinol Metab. 2024;109(2):569-580. [PubMed]2. Xu Z, et al. Updated systematic review and meta-analysis of TRT on erectile function and prostate. Front Endocrinol. 2024. [PMC Full Text]
3. Lee H, et al. Testosterone replacement in men with sexual dysfunction. Cochrane Database Syst Rev. 2024. [Cochrane Library]
4. Zhu J, et al. Do testosterone supplements enhance response to PDE5 inhibitors in men with ED and hypogonadism: A meta-analysis. Transl Androl Urol. 2020. [PMC Full Text]
5. Buvat J, et al. TADTEST Study: Hypogonadal men nonresponders to tadalafil benefit from testosterone normalization. J Sex Med. 2011. [PubMed]
6. Corona G, et al. Testosterone Therapy Improves Erectile Function and Libido in Hypogonadal Men. Curr Opin Urol. 2017. [PMC Full Text]
7. Aversa A, et al. Synergetic effect of testosterone and PDE-5 inhibitors in hypogonadal men with ED. Int J Androl. 2012. [PMC Full Text]
8. Bremelanotide (PT-141): Mechanism and clinical evidence. J Sex Med. [PMC Full Text]
9. La Vignera S, et al. Androgen Deficiency and PDE5 Expression Changes in Aging Male. Front Endocrinol. 2019. [Frontiers Full Text]
10. Relationship Between Testosterone and Erectile Dysfunction. World J Urol. [PMC Full Text]
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Sexual dysfunction can have multiple causes requiring individualized evaluation. All medications discussed require prescriptions and should be used under medical supervision. PT-141 use in men is off-label. Consult a qualified healthcare provider for personalized recommendations.
About ExcelMale.com: ExcelMale is a men's health forum with over 24,000 members and 20+ years of archived discussions on testosterone replacement therapy, hormone optimization, and sexual health. Founded by Nelson Vergel, author of Testosterone: A Man's Guide and Beyond Testosterone, ExcelMale provides evidence-based information and peer support for men navigating hormone health decisions.
Last edited:
